미국의 골관절염 치료 시장 규모, 점유율 및 동향 분석 리포트 : 제품별, 용도별, 주요 사용자별, 부문 예측(2025-2033년)

U.S. Osteoarthritis Therapeutics Market Summary

The U.S. osteoarthritis therapeutics market size was estimated at USD 2.15 billion in 2024 and is projected to reach USD 4.50 billion by 2033, growing at a CAGR of 8.61% from 2025 to 2033. Growing geriatric population, rising prevalence of obesity and joint injuries, and increasing demand for minimally invasive and regenerative therapies are driving the osteoarthritis therapeutics industry.

The aging population is a major factor driving the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in February 2024, the age-adjusted prevalence of arthritis among U.S. adults aged 18 and older was 18.9%, with the prevalence in adults aged 75 and older reaching 53.9%. As the U.S. population ages, particularly with the elderly demographic projected to represent nearly 20% of the population by 2030, the demand for osteoarthritis treatments tailored to the older age group is increasing. In September 2024, the CDC reported that 40.3% of U.S. adults were classified as obese between August 2021 and August 2023. Obesity is a significant risk factor for osteoarthritis, especially in weight-bearing joints, and its high prevalence is contributing to the rising number of osteoarthritis cases.

Additionally, the increase in joint injuries, particularly those related to sports and work-related accidents, is accelerating the onset of osteoarthritis. As more individuals engage in physical activities, the likelihood of joint damage and subsequent osteoarthritis increases. In February 2024, the International Labour Organization (ILO) estimated that approximately 395 million workers worldwide sustain non-fatal work injuries annually, many of which result in joint damage. This has increased awareness of the need for joint health management and has contributed to the rising demand for osteoarthritis therapeutics in the U.S.

Finally, the shift toward minimally invasive and regenerative therapies is playing a significant role in shaping the U.S. osteoarthritis therapeutics market. There is growing interest in non-surgical treatments, such as hyaluronic acid injections, platelet-rich plasma (PRP) therapy, and stem cell therapies, as they offer effective alternatives with shorter recovery times and fewer side effects compared to traditional surgical options. This shift in treatment preferences is expected to continue fueling market growth in the coming years.

The industry is driven by the aging population, rising obesity rates, increasing joint injuries, and a growing preference for minimally invasive and regenerative therapies. These factors are expected to support continued market growth, with advancements in treatment technologies playing a key role in meeting the demands of an aging population.

U.S. Osteoarthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. osteoarthritis therapeutics market report based on product, application, and primary user:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Viscosupplements
• Platelet-Rich Plasma (PRP) Therapy
• Bone Graft Substitutes
• BMAC (Bone Marrow Aspirate Concentrate) Therapy
• Adipose Tissue Therapy
• Autologous Chondrocyte Implantation (ACI), Including MACI
• Stem Cell (other)
• Other (Cartilage Resurfacing Products)
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Knee Osteoarthritis
• Hip Osteoarthritis
• Shoulder Osteoarthritis
• Spine Osteoarthritis
• Ankle & Foot Osteoarthritis
• Other
• Primary User Outlook (Revenue, USD Million, 2021 - 2033)
• Orthopedic Surgeons
• Rheumatologists
• Sports Medicine Specialists
• Regenerative Medicine Specialists
• Other

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Primary User
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Osteoarthritis Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Osteoarthritis Therapeutics Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2033
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Viscosupplements
  • 4.4.1. Viscosupplements Market, 2021 - 2033 (USD Million)
• 4.5. Platelet-Rich Plasma (PRP) Therapy
  • 4.5.1. Platelet-Rich Plasma (PRP) Therapy Market, 2021 - 2033 (USD Million)
• 4.6. Bone Graft Substitutes
  • 4.6.1. Bone Graft Substitutes Market, 2021 - 2033 (USD Million)
• 4.7. BMAC (Bone Marrow Aspirate Concentrate) Therapy
  • 4.7.1. BMAC (Bone Marrow Aspirate Concentrate) Therapy Market, 2021 - 2033 (USD Million)
• 4.8. Adipose Tissue Therapy
  • 4.8.1. Adipose Tissue Therapy Market, 2021 - 2033 (USD Million)
• 4.9. Autologous Chondrocyte Implantation (ACI), Including MACI
  • 4.9.1. Autologous Chondrocyte Implantation (ACI), Including MACI Market, 2021 - 2033 (USD Million)
• 4.10. Stem Cell (other)
  • 4.10.1. Stem Cell (other) Market, 2021 - 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Osteoarthritis Therapeutics Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by application, 2021 to 2033 (USD Million)
• 5.4. Knee Osteoarthritis
  • 5.4.1. Knee Osteoarthritis Market, 2021 - 2033 (USD Million)
• 5.5. Hip Osteoarthritis
  • 5.5.1. Hip Osteoarthritis Market, 2021 - 2033 (USD Million)
• 5.6. Shoulder Osteoarthritis
  • 5.6.1. Shoulder Osteoarthritis Market, 2021 - 2033 (USD Million)
• 5.7. Spine Osteoarthritis
  • 5.7.1. Spine Osteoarthritis Market, 2021 - 2033 (USD Million)
• 5.8. Ankle & Foot Osteoarthritis
  • 5.8.1. Ankle & Foot Osteoarthritis Market, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Osteoarthritis Therapeutics Market: Primary User Business Analysis

• 6.1. Primary User Market Share, 2024 & 2033
• 6.2. Primary User Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by primary user, 2021 to 2033 (USD Million)
• 6.4. Orthopedic Surgeons
  • 6.4.1. Orthopedic Surgeons Market, 2021 - 2033 (USD Million)
• 6.5. Rheumatologists
  • 6.5.1. Rheumatologists Market, 2021 - 2033 (USD Million)
• 6.6. Sports Medicine Specialists
  • 6.6.1. Sports Medicine Specialists Market, 2021 - 2033 (USD Million)
• 6.7. Regenerative Medicine Specialists
  • 6.7.1. Regenerative Medicine Specialists Market, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Stryker
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Zimmer Biomet Holdings, Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Medtronic
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Anika Therapeutics, Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Bioventus
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Vericel Corporation
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Smith & Nephew
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Fidia Farmaceutici S.p.A.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Seikagaku Corporation
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Sanofi
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives